Li Huimin

[Expert Profile] Li Huimin, Chief Physician, Professor, Doctoral Supervisor, is an authoritative expert in interstitial lung disease in China, working in the Department of Pulmonary and Critical Care Medicine, Shanghai Pulmonary Hospital. He has long been dedicated to clinical diagnosis, treatment, and scientific research of difficult pulmonary interstitial diseases and rare lung diseases, and is an important expert in the field of interstitial lung disease in China.

[Education & Career] Professor Li Huimin graduated from a renowned medical university, completed systematic clinical training at Shanghai Pulmonary Hospital, and has long been engaged in clinical and research work in respiratory medicine, particularly interstitial lung disease. He has held academic positions in the Interstitial Lung Disease Group of the Respiratory Diseases Branch of the Chinese Medical Association, and has presided over grants from the National Natural Science Foundation of China and Shanghai municipal research programs, accumulating extensive diagnosis and treatment experience in the field of interstitial lung disease.

[Areas of Expertise] Professor Li specializes in the diagnosis and treatment of various interstitial lung diseases such as idiopathic pulmonary fibrosis (IPF), nonspecific interstitial pneumonia, and cryptogenic organizing pneumonia, as well as rare lung diseases. He has extensive experience in comprehensive imaging-pathology-clinical diagnosis of interstitial lung disease, standardized application of anti-fibrotic drugs, and management of comorbidities. He excels at identifying causes through multidisciplinary discussion for difficult cases such as "ground-glass opacities, reticular opacities, and honeycomb lung," helping numerous interstitial lung disease patients slow disease progression and improve quality of life.

[Academic Achievements & Industry Contributions] Professor Li has led a series of clinical studies on interstitial lung disease, systematically evaluating the clinical characteristics, imaging subtypes, and treatment strategies of Chinese interstitial lung disease patients, with findings published in authoritative domestic and international journals. He has participated in the development of Chinese interstitial lung disease diagnosis and treatment guidelines and expert consensus statements, actively promoted the popularization of the multidisciplinary collaborative diagnosis and treatment model (MDT) for interstitial lung disease, and organized difficult case consultations and grassroots physician training, making important contributions to improving the standardized diagnosis and treatment level of interstitial lung disease in China.

[Clinical Practice & Outstanding Contributions] Professor Li has long held dedicated interstitial lung disease clinics, cumulatively treating tens of thousands of patients with various interstitial lung diseases and rare lung conditions, including many difficult cases who traveled across multiple regions seeking care. He is meticulous and responsible with patients, insisting on long-term follow-up and whole-course management, and is deeply trusted by patients. He has repeatedly organized interstitial lung disease patient education activities and free clinics, actively helping patients correctly understand their diseases and receive standardized treatment, and is a warm and reliable respiratory medicine expert in the hearts of patients.

[Honors & Reputation] Professor Li Huimin has long held academic positions in the Interstitial Lung Disease Group of the Respiratory Diseases Branch of the Chinese Medical Association. He has presided over grants from the National Natural Science Foundation of China and Shanghai municipal research programs, and is a senior expert in the field of interstitial lung disease in China. He has profound expertise in the diagnosis and treatment of idiopathic pulmonary fibrosis and rare lung diseases. He has led the establishment of a multidisciplinary diagnosis and treatment (MDT) system for interstitial lung disease, promoted standardized anti-fibrotic therapy and pulmonary function/imaging follow-up, and participated in the development of Chinese interstitial lung disease diagnosis and treatment guidelines and expert consensus statements. For decades on the clinical front lines and in patient follow-up management, he has helped numerous interstitial lung disease patients slow disease progression, and is deeply trusted by patients and respected by peers alike.